Form 4: Kezar Life Sciences Director John Fowler Reports Transactions

John Fowler, a Director at Kezar Life Sciences, Inc., reported transactions related to stock options and common stock following a merger.

Summary

• John Franklin Fowler, a Director at Kezar Life Sciences, Inc. (KZR), reported transactions on May 11, 2026.
• These transactions are in connection with a merger agreement where Aurinia Pharma U.S., Inc. acquired Kezar Life Sciences.
• The acquisition involved a tender offer for common stock at $6.955 per share in cash, plus a contingent value right (CVR).
• Out-of-the-money stock options were cancelled without consideration.
• In-the-money stock options were cancelled and converted into the right to receive cash based on the spread over the exercise price, plus one CVR per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on the execution of a pre-announced merger and the conversion of equity awards, rather than new financial performance or strategic shifts.

Positives

• Director John Fowler received cash consideration and contingent value rights for his in-the-money stock options as part of the merger.
• The merger provides a cash payout to tendering stockholders and holders of in-the-money options.

Negatives

• Out-of-the-money stock options held by the reporting person were cancelled without any compensation.
• The value of the contingent value rights (CVRs) is dependent on the achievement of specified future milestones.

Risks

• The value of the contingent value rights (CVRs) is not guaranteed and depends on the achievement of specified milestones.
• The cancellation of out-of-the-money stock options represents a loss of potential future gains for the reporting person.

Future Outlook

The future outlook for the contingent value rights (CVRs) is dependent on the achievement of specified milestones as outlined in the CVR Agreement.

Industry Context

StockSavvy.ai notes that this Form 4 filing details executive and director transactions in the context of a significant corporate event, a merger. Such filings are standard for tracking insider activity during acquisition processes and highlight the conversion of equity awards into cash and contingent rights.

Stakeholder Impact

• Shareholders who tendered shares will receive cash and CVRs.
• Holders of in-the-money stock options will receive cash and CVRs.
• Holders of out-of-the-money stock options will not receive any compensation for their options.
• The company will become a wholly owned subsidiary of Parent (Aurinia Pharma U.S., Inc.).

Next Steps

• Tendering stockholders will receive cash consideration and CVRs.
• Holders of in-the-money stock options will receive cash and CVRs.
• The value of CVRs will be realized upon the achievement of specified milestones.

Key Dates

Keywords

Kezar Life Sciences, KZR, Form 4, SEC Filing, Merger, Tender Offer, Stock Options, Contingent Value Rights, Director Transactions, John Fowler